Article
Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Oct 2012
Cadranel Jacques, Mauguen Audrey, Faller Michele, Zalcman Gérard, Buisine Marie-Pierre, Westeel Virginie, Longchampt Elisabeth, Wislez Marie, Coudert Bruno, Daniel Catherine, Chetaille Bruno, Michiels Stephane, Blons Helene, Solassol Jerome, De Fraipont Florence, Foucher Pascal, Urban Thierry, Lacroix Ludovic, Poulot Virginie, Quoix Elisabeth, Antoine Martine, Danton Guillaume, Morin Franck, Chouaid Christos, Pignon Jean-Pierre
Abstract excerpt
BACKGROUND: Epidermal growth factor and v-Ki-ras2 Kirsten ras sarcoma (KRAS) mutation status, although associated with EGFR- tyrosine kinase inhibitor (TKI) efficacy, has not been used in clinical practice until recently. The prospective Evaluation of the EGFR Mutation status for the administration of EGFR-TKIs in non small cell lung Carcinoma (ERMETIC) study aimed to implement these biomarkers in France....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.